A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.

Also called NCT05878561

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 248 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05878561
Other papers using this trial's data
  • Efficacy and Safety of Fimasartan/Indapamide Combination Therapy versus Fimasartan Monotherapy in Patients with Essential Hypertension Inadequately Responding to Fimasartan 30 mg (FINEDUO): A Randomized, Double-Blind, Multicenter, Phase III Study Drug design, development and therapy, 2026 DOI, PubMed 42163997, PMC13186222 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05878561. Randomized; double masking; primary purpose treatment. Start 2022-11-09 (actual); primary completion 2024-12-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy
Condition
Essential Hypertension
Intervention (Drug)
Fimasartan + Indapamide
Intervention (Drug)
Fimasartan + Indapamide placebo
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct05878561
Content hash
77784bc903fed03e9f313b7ea36f0c970f419537d00e16e110d1df73d9aceae1